Shanghai Yingrui Biopharma Co.,Ltd.
Home
About Us
ABOUT US
Corporate Culture
Products
APIs & Intermediates
PEG Derivatives
The others
Services
News
Company News
Industry Trends
Contact Us
NEWS CENTER
The 93rd API China opened in Chongqing
On November 12, 2025, the highly anticipated 93rd China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Fair (API China) kicked off at the Chongqing International Expo Center.
2025-11-12
2025
11-12
Shanghai has approved 8 innovative drugs of Class 1 this year
In recent years, Shanghai has continuously promoted the development of innovative drugs and ushered in a shining moment. As of 2025, a total of 8 domestically produced Class 1 innovative drugs in Shanghai have been approved for market by the National Medical Products Administration.
2025-11-01
11-01
Another wave of innovation in China's pharmaceutical industry is sweeping the nation.
With the continuous development of innovative drugs in China, it has become a trend for innovative drugs to go global. Entering October 2025, innovative drug BD transactions remain hot, with several pharmaceutical companies announcing heavyweight BD transactions on October 16th.
2025-10-20
10-20
The tide of mergers and acquisitions among global pharmaceutical companies is rising
Recently, there have been frequent mergers and acquisitions in the global pharmaceutical industry, with pharmaceutical leaders such as Bristol Myers Squibb (BMS), Novo Nordisk, and Abbott taking action one after another. Industry insiders point out that this is not an accidental capital impulse, but a strategic necessity for global pharmaceutical companies under multiple pressures such as patent cliffs and intensified market competition. Behind every merger and acquisition, there is an important
2025-10-10
10-10
CAR-T therapy, a million-dollar cancer drug, breaks the ice in medical insurance coverage.
CAR-T drugs have always been known for their exorbitant prices, with each injection costing around 1 million yuan. The issue of CAR-T drugs being included in medical insurance has also received much attention. Now, this situation has finally made a breakthrough. It is reported that on September 20th, the National Healthcare Security Administration announced that the expert review of the first edition of the commercial insurance innovative drug catalog has been completed. Among them, all 5 CAR-T
2025-09-26
09-26
In September, China's innovative drugs went global, adopting the NewCo model multiple times
NewCo may be a more suitable model for some domestic pharmaceutical companies than BD, which has been increasing from last year to this year. The fields of cancer and self immunotherapy are the main layout directions. Since September, there have been multiple incidents of NewCo going global.
2025-09-18
09-18
GLP-1 drugs receive another major boost
Recently, the World Health Organization (WHO) announced the inclusion of GLP-1 drugs and other essential medicines in its Essential Medicines List (EML), aiming to promote global accessibility of these high priced drugs. It is reported that the core active ingredients of Novo Nordisk Ozempic and Lilly Mounjaro are included in the list this time for the treatment of type 2 diabetes combined with cardiovascular disease, chronic kidney disease or obesity.
2025-09-08
09-08